文献速递临床试验与 GCP基础与转化研究

加味补肾益气方辅助全身糖皮质激素治疗慢阻肺急性加重:随机双盲多中心安慰剂对照试验方案

Efficacy and safety of Jia Wei Bushen Yiqi formulas as an adjunct therapy to systemic glucocorticoids on acute exacerbation of COPD: study protocol for a randomized, double-blinded, multi-center, placebo-controlled clinical trial.
PubMed 文献 · Trials · 2020-09-03

本研究为多中心随机双盲安慰剂对照试验,纳入慢阻肺急性加重住院患者,随机分四组比较加味补肾益气方联合5天或9天泼尼松的疗效与安全性。主要结局为180天随访内下次急性加重间隔时间和治疗期间CAT评分,次要结局包括肺功能、中医证候、实验室检查及HPA轴和炎症因子变化。

要点

  • 评价加味补肾益气方辅助全身糖皮质激素治疗慢阻肺急性加重的疗效与安全性。
  • 比较短期5天与长期9天全身糖皮质激素方案的非劣效性。
  • 主要结局为180天内下次急性加重间隔时间和治疗期间CAT评分。

核心结论

  • 该试验旨在评估加味补肾益气方辅助全身糖皮质激素对慢阻肺急性加重患者的疗效与安全性,并探讨短期5天全身糖皮质激素是否非劣于长期9天方案。

研究设计与样本

  • 多中心、随机、双盲、安慰剂对照临床试验,纳入慢阻肺急性加重住院患者,随机分为A、B、C、D四组。
  • A组接受安慰剂加5天泼尼松,B组接受安慰剂加9天泼尼松,C组接受加味补肾益气方加5天泼尼松,D组接受加味补肾益气方加9天泼尼松。

关键数值与推荐

  • 主要结局为180天随访期间患者下次急性加重的时间间隔及治疗期间慢阻肺评估测试(CAT)评分。
  • 次要结局包括肺功能、中医证候评估、实验室检查及安全性,并测量下丘脑-垂体-肾上腺(HPA)轴和炎症细胞因子的变化。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Systemic glucocorticoids are effective for the management of chronic obstructive pulmonary disease (COPD) exacerbation but have serious adverse effects. Traditional Chinese medicine (TCM) can bring additional benefits to these patients but has few adverse effects. The present study aims to evaluate the efficacy and safety of Jia Wei Bushen Yiqi (JWBY) formulas in patients who suffer from COPD exacerbations and to investigate whether the short-term (5-days) systemic glucocorticoid therapy is non-inferior to the long-term (9-day) regime. METHODS: In this multi-center, randomized, double-blinded trial, eligible inpatients with COPD exacerbation are randomly assigned to four groups (A, B, C, and D). Group A will receive placebo plus 5-day prednisone, group B will receive placebo plus 9-day prednisone, group C will receive JWBY formulas plus 5-day prednisone, and group D will receive JWBY formulas plus 9-day prednisone. The primary outcomes are the time interval to the patient's next exacerbation during a 180-day following up and the COPD assessment test (CAT) during treatment. Secondary outcomes include lung function, TCM syndrome assessment, laboratory tests, and safety. The changes of the hypothalamic pituitary adrenaline axis (HPA axis) and inflammatory cytokine will be measured as well. DISCUSSION: By demonstrating the advantages of utilizing TCM and an appropriate duration of systemic glucocorticoids, this effectiveness comparison trial will provide new references to physicians on how to improve the management of COPD exacerbation. The results of HPA axis and inflammation cytokine measurements will shed light on the molecular mechanisms and entail further mechanism studies. TRIAL REGISTRATION: www.chictr.org.cn ChiCTR1900023364. Registered on 24 May 2019.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Kong Q, Mo S, Wang W, et al. Efficacy and safety of Jia Wei Bushen Yiqi formulas as an adjunct therapy to systemic glucocorticoids on acute exacerbation of COPD: study protocol for a randomized, double-blinded, multi-center, placebo-controlled clinical trial. Trials. 2020. PMID: 32883322. doi:10.1186/s13063-020-04669-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。